Present optimal therapy in ovarian cancer.
Abrams
J
J
D000477:Alkylating Agents / Q000627:therapeutic use; D006585:Altretamine / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002945:Cisplatin / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000627:therapeutic use; D004351:Drug Resistance; D005260:Female; D006801:Humans; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000628:therapy*
D000477:Alkylating Agents; D004317:Doxorubicin; D002945:Cisplatin; D006585:Altretamine